ClinicalTrials.gg
CompletedNCT06049329Updated Mar 5, 2025

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

A Phase 1 interventional study of NNC0487-0111 and Placebo (NNC0487-0111) in Obesity, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.

Enrollment
22nd of 24
36 · median 360
Started
2023
with 1 other
Phase 1
9 of 24
6 open now
Registered
1st of 24
by date
Lead sponsor
24 of 24
Novo Nordisk A/S

Among the 24 studies testing zenagamtide in Obesity, this one is the 22nd largest by enrollment, is one of 2 that started in 2023, is one of 9 in phase 1, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About zenagamtide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing zenagamtide in Obesity, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as an oral tablet to Japanese participants.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria

  • Male with both parents of Japanese descent
  • (BMI) between 25.0 and 34.9 kg/m\^2 (both inclusive). Body weight equal to or greater than 65.0 kg
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator

Key exclusion criteria

  • Any disorder that in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
  • Presence of gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    NNC0487-0111

    Once-daily oral administration - 1 of 3 different doses

    Drug: NNC0487-0111

  • Placebo comparator
    Placebo

    Once-daily oral administration - 1 of 3 different doses

    Drug: Placebo (NNC0487-0111)

Interventions

  • Participants will get one tablet to swallow at the same time of the day.

  • DrugPlacebo (NNC0487-0111)

    Participants will get one tablet to swallow at the same time of the day.

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAE)

    Number of events

    Time frame: From pre-dose on Day 1 until completion of the end of study visit Day 31

Secondary outcomes

  1. AUC,MD; the area under the NNC0487-0111 plasma concentration-time curve after last multile dose

    h\*nmol/L

    Time frame: From pre-dose on Day 10 until Day 11 (24 hours post-dose)

  2. Cmax,MD; the maximum plasma concentration of NNC0487-0111 after last multiple dose

    nmol/L

    Time frame: From pre-dose on Day 10 until completion of the end of study visit Day 31

  3. tmax,MD; the time of maximum plasma concentration of NNC0487-0111 after last multiple dose

    hour

    Time frame: From pre-dose on Day 10 until completion of the end of study visit Day 31

07

Study locations

1 site
  • Hakata Clinic
    Fukuoka, 812-0025, Japan
08

References and documents

Individual participant data

Plan to share: Yes — "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Dec 2023, 3 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 22, 2023
StartActual
Sep 14, 2023
Primary completionActual
Dec 15, 2023
CompletionActual
Dec 15, 2023
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06049329
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Sep 14, 2023
Primary completion
Dec 15, 2023
Completion
Dec 15, 2023
Last update
Mar 5, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion